Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer

SIMPLE SUMMARY: Resistance to tamoxifen treatment is an obstacle for ER+ve breast cancer therapy. The overexpression of c-MYC is a known driver of cancer progression and is associated with tamoxifen resistance. Through mediating the up-regulation of ribosome biogenesis and alteration of the transcri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsoi, Ho, You, Chan-Ping, Leung, Man-Hong, Man, Ellen P. S., Khoo, Ui-Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909264/
https://www.ncbi.nlm.nih.gov/pubmed/35267559
http://dx.doi.org/10.3390/cancers14051251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909264/
https://www.ncbi.nlm.nih.gov/pubmed/35267559
http://dx.doi.org/10.3390/cancers14051251

Ejemplares similares